Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)

Авторы: Nathan Paul, Ascierto Paolo A., Haanen John, Espinosa Enrique, Demidov Lev, Garbe Claus, Guida Michele, Lorigan Paul, Chiarion-Sileni Vanna, Gogas Helen, Maio Michele, Fierro Maria Teresa, Hoeller Christoph, Terheyden Patrick, Gutzmer Ralf, Guren Tormod K., Bafaloukos Dimitrios, Rutkowski Piotr, Plummer Ruth, Waterston Ashita, Kaatz Martin, Mandala Mario, Marquez-Rodas Ivan, Muñoz-Couselo Eva, Dummer Reinhard, Grigoryeva Elena, Young Tina C., Schadendorf Dirk
Журнал: European Journal of Cancer
Том: 119
Год издания: 2019
Издательство: Pergamon Press Ltd.
Местоположение издательства: United Kingdom
Первая страница: 168
Последняя страница: 178
DOI: 10.1016/j.ejca.2019.07.010
Аннотация: Nivolumab has been widely studied in non-acral cutaneous melanoma; however, limited data are available in other melanoma subtypes. We report outcomes by melanoma subtype in patients who received nivolumab after progression on prior ipilimumab.
Добавил в систему: Демидов Лев Вадимович

	ИСТИНА	Войти в систему Регистрация
	ИСТИНА ЦЭМИ РАН
	Главная Поиск Статистика О проекте Помощь

ИСТИНА